Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,385 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Granulocyte-colony stimulating factor Clear all

Conditions: AML, ALL, MDS, MPD Withou Myelofibrosis, NHL or HL, Inherited Metabolic Disorders, Hemoglobinopathies, Bone Marrow Failure, HLH
Interventions: Clofarabine, Fludarabine, Busulfan, Cyclosporine-A, Mycophenolate Mofetil, Cord Blood Graft; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Biological · Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Triple-negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more

Conditions: Lung Cancer
Interventions: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Retinoblastoma
Interventions: filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, autologous bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 15 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Sipuleucel-T; Biological
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
Interventions: Brentuximab Vedotin, Bendamustine, Neulasta; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: filgrastim, rituximab; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sarcoma
Interventions: dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2011
U.S. locations: 205
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
Interventions: Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, Pegfilgrastim; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, ifosfamide, imatinib mesylate, leucovorin calcium, mercaptopurine tablet, methotrexate, pegaspargase, vincristine sulfate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Melanoma (Skin)
Interventions: Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neuroblastoma
Interventions: ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin; Biological · Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Up to 8 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 2 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Madera, California + 52 more

Conditions: HIV Infections
Interventions: Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2008
U.S. locations: 11
States / cities: Chicago, Illinois • St Louis, Missouri • New York, New York + 6 more

Conditions: Prostatic Neoplasms
Interventions: Mitoxantrone, GM-CSF; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 59 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome; Procedure · Drug · Radiation + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 169
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more

Conditions: AIDS Related Lymphoma, AIDS-Associated Lymphoma
Interventions: Filgrastim, Rituximab, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuroblastoma
Interventions: filgrastim, monoclonal antibody 3F8, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, perfosfamide, vincristine sulfate, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radioisotope therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Neutropenia (Low White Blood Cell Count)
Interventions: Filgrastim Hospira (US), US-approved Neupogen®; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head and Neck Cancer
Interventions: filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 216
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more

Search by objective public record fields.

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer